— Review of Phase I ready BMB-101 and upcoming milestones — — Webcast to be held on May 19, 2022, 4:00pm ET — VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain…

Source

Previous articleBright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties
Next articleNuminus Applies for International Patent Filing of Psychedelics Production Process